The gist: AltPep CEO Valerie Daggett envisions a future where people are routinely screened for Alzheimer’s disease before cognitive symptoms develop, and potentially even receive preventive treatment. Last fall, the company published data showing that its experimental test could detect signs of disease in the blood of people with Alzheimer’s disease and in people who went on to develop mild cognitive impairment. The test is now on track for priority review with the U.S. Food and Drug Administration.